#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Clear cell papillary renal cell carcinoma Severe myoclonic epilepsy of infancy Familial hypertriglyceridaemia Hereditary optic atrophy Juvenile chronic myelomonocytic leukaemia Thrombocytosis Primary biliary cholangitis Neoplasm Leukaemia Philadelphia positive chronic myeloid leukaemia Gastrointestinal disorder C3 glomerulopathy Glomerulonephritis membranoproliferative Skin angiosarcoma Metastatic gastric cancer More trials…

    Learn about Rare Diseases

    Ehlers-Danlos syndrome – Trials in Disease Wolfram syndrome – Diagnostics Piriformis syndrome – Basic Information Waldenstrom’s macroglobulinaemia refractory – Treatment Nephroblastoma – Life with Disease Rhabdoid tumour – Life with Disease Osteosarcoma recurrent – Trials in Disease Mastocytosis Shprintzen-Goldberg syndrome – Basic Information Systemic mastocytosis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Elritercept GOVORESTAT Doravirine Db-Oto-3 Anhydrous Benzoyl Peroxide Golexanolone Grwd5769 Vincristine Florbetapir (18F) JX10 Anakinra Oxazepam Glucose, Anhydrous Histidine Spesolimab Itolizumab Tildacerfont Milademetan Rct2100 Zinc Oxide More therapies…

    Learn about Your Condition

    Corneal graft failure Corneal dystrophy Type 1 diabetes mellitus Colorectal adenoma Weaning failure Anal incontinence Blood disorder Aortic valve stenosis Hypercholesterolaemia Inflammation Athetosis Escherichia infection Hysterectomy Endometrial cancer stage II Anal fissure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Hospitalier Departemental Vendee

Centre Hospitalier Departemental Vendee

Boulevard Stephane Moreau, La Roche sur Yon, 85925, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of fianlimab plus cemiplimab with chemotherapy or cemiplimab with chemotherapy for patients with pleural mesothelioma who have not received prior treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Pleural mesothelioma
    Investigated Drugs:
    • Fianlimab
    • Cemiplimab
    France

  • A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    • Belzutifan
    • Cabozantinib
    Austria Belgium Croatia Czechia Denmark France +6

  • A Study of Datopotamab Deruxtecan for Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer That Did Not Respond to Hormone Therapy

    Recruiting

    2 1 1
    Investigated Drugs:
    • Datopotamab Deruxtecan
    France Italy Spain

  • Study of Methotrexate Treatment for Patients with Erosive Hand Osteoarthritis Not Responding to Standard Therapy

    Recruiting

    2 1 1
    Investigated Diseases:
    • Osteoarthritis
    Investigated Drugs:
    • Folic Acid
    • Sodium Chloride Solution 0.9%
    • Methotrexate
    France

  • Study of nirsevimab and RSV vaccine (Abrysvo) for prevention of respiratory syncytial virus infection in infants during their first year of life

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Bronchiolitis
    • Respiratory syncytial virus infection
    France

  • Study of bevacizumab and trifluridine combination given bi-weekly to reduce severe neutropenia in patients with metastatic colorectal cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal adenocarcinoma
    Investigated Drugs:
    • Bevacizumab
    • Trifluridine
    France

  • Study of FOLFOX or FOLFIRI chemotherapy with fruquintinib or bevacizumab as second-line treatment for patients with metastatic colorectal cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • FRUQUINTINIB
    • Bevacizumab
    • Fluorouracil
    France

  • Study of felzartamab compared to placebo in adults with IgA nephropathy

    Recruiting

    3 1 1
    Investigated Drugs:
    • Fexofenadine
    • Felzartamab
    • Desloratadine
    Belgium Bulgaria Croatia Czechia France Germany +5

  • Study of Atacicept Treatment for Patients with Multiple Autoimmune Glomerular Diseases

    Recruiting

    2 1 1
    Investigated Drugs:
    • Atacicept
    Belgium France Germany Italy Poland Spain

  • Comparing rifampin-free treatment versus rifampin in adults with staphylococcal prosthetic valve endocarditis

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • CEFTAROLINE FOSAMIL
    • Daptomycin
    • Rifampicin
    France
Previous Page
1 2 3 4 … 21
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!